Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Int J Oncol

Retrieve available abstracts of 56 articles:
HTML format
Text format



Single Articles


    October 2017
  1. RATAJCZAK-WIELGOMAS K, Grzegrzolka J, Piotrowska A, Matkowski R, et al
    Expression of periostin in breast cancer cells.
    Int J Oncol. 2017;51:1300-1310.
    PubMed     Text format     Abstract available


  2. YIN H, Zhu Q, Liu M, Tu G, et al
    GPER promotes tamoxifen-resistance in ER+ breast cancer cells by reduced Bim proteins through MAPK/Erk-TRIM2 signaling axis.
    Int J Oncol. 2017;51:1191-1198.
    PubMed     Text format     Abstract available


  3. PHILLIPS SL, Williams CB, Zambrano JN, Williams CJ, et al
    Connexin 43 in the development and progression of breast cancer: What's the connection? (Review).
    Int J Oncol. 2017;51:1005-1013.
    PubMed     Text format     Abstract available


    September 2017
  4. D'ANGELO S, Martino E, Ilisso CP, Bagarolo ML, et al
    Pro-oxidant and pro-apoptotic activity of polyphenol extract from Annurca apple and its underlying mechanisms in human breast cancer cells.
    Int J Oncol. 2017;51:939-948.
    PubMed     Text format     Abstract available


  5. OBAYASHI S, Horiguchi J, Higuchi T, Katayama A, et al
    Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients.
    Int J Oncol. 2017;51:781-790.
    PubMed     Text format     Abstract available



  6. [Corrigendum] Transcriptome sequencing of human breast cancer reveals aberrant intronic transcription in amplicons and dysregulation of alternative splicing with major therapeutic implications.
    Int J Oncol. 2017;51:997-0.
    PubMed     Text format     Abstract available


    August 2017
  7. ILKOVICOVA L, Trost N, Szentpeteriova E, Solar P, et al
    Overexpression of the erythropoietin receptor in RAMA 37 breast cancer cells alters cell growth and sensitivity to tamoxifen.
    Int J Oncol. 2017;51:737-746.
    PubMed     Text format     Abstract available


    July 2017
  8. WANG Y, Wang H, Ding Y, Li Y, et al
    N-peptide of vMIP- reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer.
    Int J Oncol. 2017 Jul 19. doi: 10.3892/ijo.2017.4076.
    PubMed     Text format     Abstract available


  9. LI SJ, Liu CS, Li HJ, Li Y, et al
    A novel engineered interferon-alpha hybrid molecule increases anticancer efficacy of doxorubicin in breast cancer chemotherapy.
    Int J Oncol. 2017 Jul 3. doi: 10.3892/ijo.2017.4062.
    PubMed     Text format     Abstract available


    June 2017
  10. KIM DH, Sung B, Kim JA, Kang YJ, et al
    HS-1793, a resveratrol analogue, downregulates the expression of hypoxia-induced HIF-1 and VEGF and inhibits tumor growth of human breast cancer cells in a nude mouse xenograft model.
    Int J Oncol. 2017 Jun 27. doi: 10.3892/ijo.2017.4058.
    PubMed     Text format     Abstract available


  11. NOWAK A, Grzegrzolka J, Paprocka M, Piotrowska A, et al
    Nestin-positive microvessel density is an independent prognostic factor in breast cancer.
    Int J Oncol. 2017 Jun 26. doi: 10.3892/ijo.2017.4057.
    PubMed     Text format     Abstract available


  12. YAO M, Yuan B, Wang X, Sato A, et al
    Synergistic cytotoxic effects of arsenite and tetrandrine in human breast cancer cell line MCF-7.
    Int J Oncol. 2017 Jun 23. doi: 10.3892/ijo.2017.4052.
    PubMed     Text format     Abstract available


    May 2017
  13. LIANG N, Li Y, Chung HY
    Two natural eudesmane-type sesquiterpenes from Laggera alata inhibit angiogenesis and suppress breast cancer cell migration through VEGF- and Angiopoietin 2-mediated signaling pathways.
    Int J Oncol. 2017 May 17. doi: 10.3892/ijo.2017.4004.
    PubMed     Text format     Abstract available


  14. LINDSTEN T, Hedbrant A, Ramberg A, Wijkander J, et al
    Effect of macrophages on breast cancer cell proliferation, and on expression of hormone receptors, uPAR and HER-2.
    Int J Oncol. 2017 May 11. doi: 10.3892/ijo.2017.3996.
    PubMed     Text format     Abstract available


  15. DING Y, Zhang C, Zhang J, Zhang N, et al
    miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-beta1 expression.
    Int J Oncol. 2017;50:1701-1710.
    PubMed     Text format     Abstract available


  16. NGUYEN CH, Huttary N, Atanasov AG, Chatuphonprasert W, et al
    Fenofibrate inhibits tumour intravasation by several independent mechanisms in a 3-dimensional co-culture model.
    Int J Oncol. 2017;50:1879-1888.
    PubMed     Text format     Abstract available


    April 2017
  17. MCDERMOTT MSJ, Canonici A, Ivers L, Browne BC, et al
    Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
    Int J Oncol. 2017 Apr 26. doi: 10.3892/ijo.2017.3976.
    PubMed     Text format     Abstract available


    March 2017
  18. XI J, Feng J, Li Q, Li X, et al
    The long non-coding RNA lncFOXO1 suppresses growth of human breast cancer cells through association with BAP1.
    Int J Oncol. 2017 Mar 24. doi: 10.3892/ijo.2017.3933.
    PubMed     Text format     Abstract available


  19. OKAMOTO K, Tanaka Y, Tsuneoka M
    SF-KDM2A binds to ribosomal RNA gene promoter, reduces H4K20me3 level, and elevates ribosomal RNA transcription in breast cancer cells.
    Int J Oncol. 2017 Mar 10. doi: 10.3892/ijo.2017.3908.
    PubMed     Text format     Abstract available


  20. GIL EY, Jo UH, Jeong H, Whang YM, et al
    [Corrigendum] Promoter methylation of RASSF1A modulates the effect of the microtubule-targeting agent docetaxel in breast cancer.
    Int J Oncol. 2017 Mar 7. doi: 10.3892/ijo.2017.3900.
    PubMed     Text format     Abstract available


  21. ZHENG X, Wang C, Xing Y, Chen S, et al
    SB-T-121205, a next-generation taxane, enhances apoptosis and inhibits migration/invasion in MCF-7/PTX cells.
    Int J Oncol. 2017;50:893-902.
    PubMed     Text format     Abstract available


    February 2017
  22. PANAGOPOULOS V, Leach DA, Zinonos I, Ponomarev V, et al
    Inflammatory peroxidases promote breast cancer progression in mice via regulation of the tumour microenvironment.
    Int J Oncol. 2017 Feb 20. doi: 10.3892/ijo.2017.3883.
    PubMed     Text format     Abstract available


  23. LANGO-CHAVARRIA M, Chimal-Ramirez GK, Ruiz-Tachiquin ME, Espinoza-Sanchez NA, et al
    A 22q11.2 amplification in the region encoding microRNA-650 correlates with the epithelial to mesenchymal transition in breast cancer primary cultures of Mexican patients.
    Int J Oncol. 2017;50:432-440.
    PubMed     Text format     Abstract available


  24. GUERRIERO E, Sorice A, Capone F, Storti G, et al
    Combining doxorubicin with a phenolic extract from flaxseed oil: Evaluation of the effect on two breast cancer cell lines.
    Int J Oncol. 2017;50:468-476.
    PubMed     Text format     Abstract available


    January 2017
  25. TRIANTAFILLU UL, Park S, Klaassen NL, Raddatz AD, et al
    Fluid shear stress induces cancer stem cell-like phenotype in MCF7 breast cancer cell line without inducing epithelial to mesenchymal transition.
    Int J Oncol. 2017 Jan 30. doi: 10.3892/ijo.2017.3865.
    PubMed     Text format     Abstract available


  26. JIANG W, Li X, Li T, Wang H, et al
    Repositioning of amprenavir as a novel extracellular signal-regulated kinase-2 inhibitor and apoptosis inducer in MCF-7 human breast cancer.
    Int J Oncol. 2017 Jan 24. doi: 10.3892/ijo.2017.3860.
    PubMed     Text format     Abstract available


    December 2016
  27. MAXWELL T, Chun SY, Lee KS, Kim S, et al
    The anti-metastatic effects of the phytoestrogen arctigenin on human breast cancer cell lines regardless of the status of ER expression.
    Int J Oncol. 2016 Dec 29. doi: 10.3892/ijo.2016.3825.
    PubMed     Text format     Abstract available


  28. NAKAYAMA J, Ito E, Fujimoto J, Watanabe S, et al
    Comparative analysis of gene regulatory networks of highly metastatic breast cancer cells established by orthotopic transplantation and intra-circulation injection.
    Int J Oncol. 2016 Dec 16. doi: 10.3892/ijo.2016.3809.
    PubMed     Text format     Abstract available


  29. PARK JH, Kim HK, Jung H, Kim KH, et al
    NecroX-5 prevents breast cancer metastasis by AKT inhibition via reducing intracellular calcium levels.
    Int J Oncol. 2016 Dec 5. doi: 10.3892/ijo.2016.3789.
    PubMed     Text format     Abstract available


    November 2016
  30. SHYAMASUNDAR S, Lim JP, Bay BH
    miR-93 inhibits the invasive potential of triple-negative breast cancer cells in vitro via protein kinase WNK1.
    Int J Oncol. 2016 Nov 7. doi: 10.3892/ijo.2016.3761.
    PubMed     Text format     Abstract available


  31. GOMULKIEWICZ A, Jablonska K, Pula B, Grzegrzolka J, et al
    Expression of metallothionein 3 in ductal breast cancer.
    Int J Oncol. 2016 Nov 4. doi: 10.3892/ijo.2016.3759.
    PubMed     Text format     Abstract available


    October 2016
  32. ZHOU H, Li J, Zhang Z, Ye R, et al
    RING1 and YY1 binding protein suppresses breast cancer growth and metastasis.
    Int J Oncol. 2016 Oct 5. doi: 10.3892/ijo.2016.3718.
    PubMed     Text format     Abstract available


    September 2016
  33. MEJIA-RANGEL J, Cordova E, Orozco L, Ventura-Gallegos JL, et al
    Pro-adhesive phenotype of normal endothelial cells responding to metastatic breast cancer cell conditioned medium is linked to NFkappaB-mediated transcriptomic regulation.
    Int J Oncol. 2016 Sep 26. doi: 10.3892/ijo.2016.3705.
    PubMed     Text format     Abstract available


  34. DING J, Guo C, Hu P, Chen J, et al
    CSF1 is involved in breast cancer progression through inducing monocyte differentiation and homing.
    Int J Oncol. 2016 Sep 6. doi: 10.3892/ijo.2016.3680.
    PubMed     Text format     Abstract available


  35. LIU ZG, Tang J, Chen Z, Zhang H, et al
    The novel mTORC1/2 dual inhibitor INK128 enhances radiosensitivity of breast cancer cell line MCF-7.
    Int J Oncol. 2016;49:1039-45.
    PubMed     Text format     Abstract available


  36. ZHAO Q, Zhao M, Parris AB, Xing Y, et al
    Genistein targets the cancerous inhibitor of PP2A to induce growth inhibition and apoptosis in breast cancer cells.
    Int J Oncol. 2016;49:1203-10.
    PubMed     Text format     Abstract available


  37. PARK JH, Cho YY, Yoon SW, Park B, et al
    Suppression of MMP-9 and FAK expression by pomolic acid via blocking of NF-kappaB/ERK/mTOR signaling pathways in growth factor-stimulated human breast cancer cells.
    Int J Oncol. 2016;49:1230-40.
    PubMed     Text format     Abstract available


  38. GALLARDO M, Calaf GM
    Curcumin inhibits invasive capabilities through epithelial mesenchymal transition in breast cancer cell lines.
    Int J Oncol. 2016;49:1019-27.
    PubMed     Text format     Abstract available


  39. IBRAHIM T, Liverani C, Mercatali L, Sacanna E, et al
    [Corrigendum] Cisplatin in combination with zoledronic acid: A synergistic effect in triple-negative breast cancer cell lines.
    Int J Oncol. 2016;49:1260.
    PubMed     Text format     Abstract available


  40. CHA J, Roomi MW, Kalinovsky T, Niedzwiecki A, et al
    Lipoprotein(a) and vitamin C impair development of breast cancer tumors in Lp(a)+; Gulo-/- mice.
    Int J Oncol. 2016;49:895-902.
    PubMed     Text format     Abstract available


  41. PARK HJ, Kim MK, Choi KS, Jeong JW, et al
    Neuromedin B receptor antagonism inhibits migration, invasion, and epithelial-mesenchymal transition of breast cancer cells.
    Int J Oncol. 2016;49:934-42.
    PubMed     Text format     Abstract available


    August 2016
  42. MIYAHARA K, Kazama H, Kokuba H, Komatsu S, et al
    Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines.
    Int J Oncol. 2016 Aug 29. doi: 10.3892/ijo.2016.3673.
    PubMed     Text format     Abstract available


  43. HE DX, Zhang GY, Gu XT, Mao AQ, et al
    Genome-wide profiling of long non-coding RNA expression patterns in anthracycline-resistant breast cancer cells.
    Int J Oncol. 2016 Aug 22. doi: 10.3892/ijo.2016.3665.
    PubMed     Text format     Abstract available


  44. KARIYA Y, Tatsuta T, Sugawara S, Kariya Y, et al
    RNase activity of sialic acid-binding lectin from bullfrog eggs drives antitumor effect via the activation of p38 MAPK to caspase-3/7 signaling pathway in human breast cancer cells.
    Int J Oncol. 2016 Aug 11. doi: 10.3892/ijo.2016.3656.
    PubMed     Text format     Abstract available


  45. CHOI YJ, Heo K, Park HS, Yang KM, et al
    The resveratrol analog HS-1793 enhances radiosensitivity of mouse-derived breast cancer cells under hypoxic conditions.
    Int J Oncol. 2016 Aug 3. doi: 10.3892/ijo.2016.3647.
    PubMed     Text format     Abstract available


    July 2016
  46. XU H, Wu K, Tian Y, Liu Q, et al
    CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer.
    Int J Oncol. 2016 Jul 29. doi: 10.3892/ijo.2016.3639.
    PubMed     Text format     Abstract available


  47. SULAIMAN NB, Mohan CD, Basappa S, Pandey V, et al
    An azaspirane derivative suppresses growth and induces apoptosis of ER-positive and ER-negative breast cancer cells through the modulation of JAK2/STAT3 signaling pathway.
    Int J Oncol. 2016 Jul 6. doi: 10.3892/ijo.2016.3615.
    PubMed     Text format     Abstract available


    June 2016
  48. KIM B, Kim YC, Park B
    Pomolic acid inhibits metastasis of HER2 overexpressing breast cancer cells through inactivation of the ERK pathway.
    Int J Oncol. 2016 Jun 7. doi: 10.3892/ijo.2016.3568.
    PubMed     Text format     Abstract available


  49. PILCO-FERRETO N, Calaf GM
    Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines.
    Int J Oncol. 2016 Jun 3. doi: 10.3892/ijo.2016.3558.
    PubMed     Text format     Abstract available


    May 2016
  50. PARK JH, Jang M, Tarhan YE, Katagiri T, et al
    Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy.
    Int J Oncol. 2016 May 27. doi: 10.3892/ijo.2016.3540.
    PubMed     Text format     Abstract available


  51. YAMAGUCHI M, Osuka S, Weitzmann MN, Shoji M, et al
    Increased regucalcin gene expression extends survival in breast cancer patients: Overexpression of regucalcin suppresses the proliferation and metastatic bone activity in MDA-MB-231 human breast cancer cells in vitro.
    Int J Oncol. 2016 May 24. doi: 10.3892/ijo.2016.3538.
    PubMed     Text format     Abstract available


  52. MENG X, Hu B, Hossain MM, Chen G, et al
    ADAM17-siRNA inhibits MCF-7 breast cancer through EGFR-PI3K-AKT activation.
    Int J Oncol. 2016 May 24. doi: 10.3892/ijo.2016.3536.
    PubMed     Text format     Abstract available


  53. CHEN SY, Zheng XW, Cai JX, Zhang WP, et al
    Histone deacetylase inhibitor reverses multidrug resistance by attenuating the nucleophosmin level through PI3K/Akt pathway in breast cancer.
    Int J Oncol. 2016 May 17. doi: 10.3892/ijo.2016.3528.
    PubMed     Text format     Abstract available


  54. WOODMAN N, Pinder SE, Tajadura V, Le Bourhis X, et al
    Two E-selectin ligands, BST-2 and LGALS3BP, predict metastasis and poor survival of ER-negative breast cancer.
    Int J Oncol. 2016 May 13. doi: 10.3892/ijo.2016.3521.
    PubMed     Text format     Abstract available


  55. KWON YS, Lee KS, Chun SY, Jang TJ, et al
    Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
    Int J Oncol. 2016 May 13. doi: 10.3892/ijo.2016.3520.
    PubMed     Text format     Abstract available


  56. GARCIA EP, Tiscornia I, Libisch G, Trajtenberg F, et al
    MUC5B silencing reduces chemo-resistance of MCF-7 breast tumor cells and impairs maturation of dendritic cells.
    Int J Oncol. 2016;48:2113-23.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: